Table 3 Changes in treatment for patients not at target at 6 months by target achievement at 12 months
From: Individualised treatment targets in patients with type-2 diabetes and hypertension
Target achieved at 12 months (N = 763) | Target not achieved at 12 months (N = 2136) | |||
|---|---|---|---|---|
6 months % (Δ from BL) | 12 months % (Δ from 6 mo) | 6 months % (Δ from BL) | 12 months % (Δ from 6 mo) | |
Metformin | 82.3 (− 0.9) | 82.3 (–) | 82.6 (−0.6) | 81.7 (−0.9) |
Sulfonylurea | 20.8 (+ 0.2) | 20.1 (− 0.7) | 20.9 (+ 0.3) | 20.7 (− 0.2) |
Glucosidase inhibitor | 1.6 (+ 1.4) | 1.3 (− 0.3) | 1.0 (− 0.2) | 0.9 (− 0.1) |
Glinide | 3.5 (− 0.6) | 3.5 (–) | 4.6 (+ 0.5) | 5.0 (+ 0.4) |
Glitazone | 0.7 (+ 0.3) | 0.8 (+ 0.1) | 0.2 (− 0.2) | 0.3 (+ 0.1) |
DPP-4 inhibitor | 63.0 (− 2.8) | 62.3 (− 0.7) | 66.7 (+ 0.9) | 64.8 (− 1.9) |
GLP-1 analogue | 6.9 (+ 1.1) | 6.6 (− 0.3) | 6.1 (+ 0.3) | 5.8 (− 0.3) |
SGLT-2 inhibitor | 1.7 (− 1.0) | 2.2 (+ 0.5) | 3.9 (+ 1.2) | 4.3 (+ 0.4) |
Any insulin | 21.2 (+ 1.8) | 24.6 (+ 3.4) | 25.0 (+ 5.6) | 29.9 (+ 4.9) |